# Rezolute Completes Phase 3 upLIFT Trial Enrollment for Ersodetug

- URL: https://stocks.freetheai.org/news/rezolute-completes-phase-3-uplift-trial-enrollment-for-ersodetug-01163e
- Published: 2026-10-14T20:05:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:RZLT](https://stocks.freetheai.org/symbols/NASDAQ-RZLT)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Rezolute, Inc. (RZLT) has completed patient enrollment in its Phase 3 upLIFT study evaluating ersodetug for the treatment of tumor hyperinsulinism. The late-stage trial finished recruiting with 16 participants in its single-arm, open-label study.

The trial measures whether ersodetug can produce at least a 50% reduction in glucose infusion rates, with success defined by a responder rate whose confidence interval lower bound reaches at least 30%. In preliminary data from the study, 7 of the first 8 enrolled patients successfully met this primary responder benchmark.

Investors and healthcare providers are now awaiting topline data from the trial, which the company expects to report in mid-December 2026. A favorable trial outcome could pave the way for regulatory steps in 2027. Shares of Rezolute, Inc. fell 7.27% to $4.275 following the announcement.

## Key points

- Rezolute, Inc. fully enrolled 16 participants in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.
- Preliminary data showed 7 of the first 8 participants achieved the primary endpoint of a 50% or greater reduction in glucose infusion rate.
- Topline trial results from the single-arm, open-label study are expected in mid-December 2026.
- A successful readout could support potential regulatory progress in 2027.
- Rezolute stock fell 7.27% to $4.275 on the day of the announcement.

## Questions and answers

### When will Rezolute release Phase 3 upLIFT trial results for ersodetug?

Rezolute expects to release topline results for the Phase 3 upLIFT study in mid-December 2026.

### What is the primary endpoint of the Phase 3 upLIFT study?

The primary endpoint is achieving a 50% or greater reduction in glucose infusion rate, with a responder rate whose confidence interval lower bound is at least 30%.

### How many patients enrolled in the Phase 3 upLIFT study?

The Phase 3 upLIFT study fully enrolled a total of 16 participants.